Moderna
Search results
We are committed to improving the health of people worldwide with our fundamental research and development of immunotherapies. We believe in scientific rigor, innovation and passion as driving force. BioNTech was founded by scientists and physicians to translate science into survival by combining fundamental research and operational excellence.
- Our Senior Team
Prof. Pedro L. Alonso, M.D., Ph.D., joined BioNTech in 2023...
- Open Positions
BioNTech SE An der Goldgrube 12 55131 Mainz, Germany. T: +49...
- Vision & Mission
BioNTech’s portfolio contains more than 25 product...
- Newsroom
First BioNTainer arrives in Rwanda - Sierk Poetting and...
- Therapeutic Areas
BioNTech initiated a clinical phase 1 trial for an...
- Connect
You are also welcome to report to BioNTech directly or to...
- History
The Pfizer-BioNTech COVID-19 vaccine is the first vaccine to...
- Pipeline
BioNTech SE An der Goldgrube 12 55131 Mainz, Germany. T: +49...
- Collaborators
Autolus Therapeutics. In February 2024, we entered into a...
- Our Senior Team
BioNTech SE (/ b iː ˈ ɒ n t ɛ k / bee-ON-tek; or / b aɪ ˈ ɒ n t ɛ k / bye-ON-tek short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
- 2008; 15 years ago
- Mainz, Germany
- 4,530 (2022)
- Biotechnology
Dec 11, 2020 · 2024. Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older. Monday, August 23, 2021 - 11:57am. View pdf copy Copy to clipboard Open in tab. COMIRNATY is the first COVID-19 vaccine to be granted FDA approval.
Aug 23, 2021 · August 23, 2021. Español. Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be...
Sep 22, 2021 · Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to allow for use of a single booster dose, to be administered...
A clinical trial demonstrated that the vaccine has an efficacy rate of over 90 percent in preventing Covid-19. Producing a batch of the Pfizer-BioNTech vaccine currently takes 60 days.
Oct 26, 2023 · NEW YORK & MAINZ, GERMANY-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study ( NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.
